Effect of Netarsudil vs Brimonidine in NTG Patients on Latanoprost

Description

A randomized, multicenter, investigator-masked prospective study of NTG patients currently on latanoprost 0.005% monotherapy, to study the effect of IOP change with the introduction of netarsudil 0.02% vs brimonidine 0.1%. Subjects will be assessed at a screening visit, and 1 follow-up visit. Clinical evaluations will include visual acuity and IOP .

Conditions

Normal Tension Glaucoma

Talk to us

Study Overview

On this page

Study Details

Study overview

A randomized, multicenter, investigator-masked prospective study of NTG patients currently on latanoprost 0.005% monotherapy, to study the effect of IOP change with the introduction of netarsudil 0.02% vs brimonidine 0.1%. Subjects will be assessed at a screening visit, and 1 follow-up visit. Clinical evaluations will include visual acuity and IOP .

Effect of the Addition of Netarsudil 0.02% vs. Brimonidine 0.1% in Normal Tension Glaucoma Patients Currently on Latanoprost 0.005%

Effect of Netarsudil vs Brimonidine in NTG Patients on Latanoprost

Condition
Normal Tension Glaucoma
Intervention / Treatment

-

Contacts and Locations

Austin

Westlake Eye Specialists - Austin Office, Austin, Texas, United States, 78746

Killeen

Westlake Eye Specialists - Killeen Office, Killeen, Texas, United States, 76549

Kyle

Westlake Eye Specialists - Kyle Office, Kyle, Texas, United States, 78640

New Braunfels

Westlake Eye Specialists - New Braunfels Office, New Braunfels, Texas, United States, 78130

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Patients 18 years and older
  • * Diagnosed with normal tension glaucoma based on the following:
  • * IOP ≤ 21mmHg
  • * Optic nerve rim thinning and/or retinal nerve fiber layer (RNFL) loss consistent with glaucoma
  • * Normal visual field OR visual field loss consistent with optic nerve or RNFL defects within the last year
  • * Open angles assessed by gonioscopy
  • * Have been on latanoprost monotherapy for at least 6 weeks
  • * Patients with angle closure glaucoma or secondary forms of glaucoma due to neovascularization of the angle, uveitic glaucoma, congenital glaucoma, or glaucoma due to congenital anomalies.
  • * Other forms of secondary glaucoma.
  • * Patients with abnormal anterior segment examination other than cataract will be excluded from the study.
  • * Patients who have had incisional surgery for glaucoma (eg: MIGs).
  • * Patients with refractory CME or CME persisting 3 months or more.
  • * Children, cognitive impaired and critically ill subjects will not be enrolled.
  • * Central Corneal Thickness (CCT) ≤ 500.
  • * Prior allergy to brimonidine or netarsudil, and known to have previously failed either brimonidine or netarsudil.
  • * Ocular surgery (e.g., cataract, laser, refractive) during the study or 1 year prior to entering the study.

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

Westlake Eye Specialists,

Zarmeena Vendal, MD, PRINCIPAL_INVESTIGATOR, Westlake Eye Specialists

Study Record Dates

2025-06-30